SOE 2023: What new surgeries will hit the glaucoma market?
June 17th 2023Ophthalmology Times Europe© is proud to cover the European Society of Ophthalmology 2023. We spoke to SOE presenter Panayiota Founti, PhD, FEBO, Consultant Ophthalmic Surgeon & Training Director, Glaucoma Service Moorfields Eye Hospital, London, UK.
COPHy 2023: Presence of macular neovascularisation on OCTA is predictive of subsequent exudation
March 24th 2023Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.
Angiogenesis: High-dose aflibercept demonstrates safety, efficacy in treatment of DME
February 28th 2023David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
Angiogenesis 2023: What the Talon Phase 3b study results mean for neovascular AMD
February 10th 2023Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
September 27th 2022Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."